risks of using semaglutide Effect 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity - Wilkinson - 2023 - Obesity Is Ozempic (Semaglutide) Lower the

& Ronai, Z

Ghosh A (2017) Genome-wide identification of glyoxalase genes in Medicago truncatula and their expression profiling in response to various developmental and environmental stimuli

Novo Nordisk and Eli Lilly are ranked #1-2 based on GLP-1/GIP market dominance (57.4% combined share)

Plant Cell Environ 40(2):180189

Note that the peak concentration occurs when the absorption rate is equal to the elimination rate at around 1.5 hours

A Market Heating Up: The Race With Novo Nordisk The obesity and diabetes drug market could reach almost $100 billion by the 2030s , and Eli Lilly wants to stay ahead of its top competitor, Novo Nordisk